Bailard’s Definium Therapeutics DFTX Stock Holding History

Bailard’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$239K	Hold	6,277	–	–	﹤0.01%	680
2026 Q2	$295K	Buy	+6,277	New	+$155K	0.01%	645
2025 Q3	–	Sell	-14,600	Closed	-$94.8K	–	845
2025 Q2	$94.8K	Hold	14,600	–	–	﹤0.01%	741
2025 Q1	$85.4K	Hold	14,600	–	–	﹤0.01%	722
2024 Q4	$102K	Sell	14,600 -9,500	-39%	-$65.4K	﹤0.01%	716
2024 Q3	$137K	Hold	24,100	–	–	﹤0.01%	721
2024 Q2	$174K	Hold	24,100	–	–	﹤0.01%	695
2024 Q1	$227K	Buy	24,100 +6,800	+39%	+$38.8K	0.01%	658
2023 Q4	$63.3K	Buy	+17,300	New	+$52.1K	﹤0.01%	698

Other funds holding DFTX

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

SCI

Stableford Capital II Scottsdale, Arizona $288M AUM 21.3% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

FSBI

Fearless Solutions (Best Invest) San Antonio, Texas $197M AUM 23.54% 1-Year Est. Return

AHL

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

CCM

Chiron Capital Management Tallahassee, Florida $101M AUM

Fiduciary Alliance Greenville, South Carolina $1.33B AUM 15.58% 1-Year Est. Return

Bailard's DFTX Position: Q3 2026 in Review

Bailard held its Definium Therapeutics (DFTX) position steady in Q3 2026 at 6,277 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #680.

Bailard first reported a position in DFTX in Q4 2023 and has held it in 9 quarters since. The position peaked at $295K in Q2 2026. 29 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

Bailard held 6,277 shares of Definium Therapeutics worth $239K as of Q3 2026.
Bailard left its Definium Therapeutics share count unchanged in Q3 2026.
Definium Therapeutics made up ﹤0.01% of Bailard's portfolio in Q3 2026, its #680 holding.
Bailard first reported a position in Definium Therapeutics in Q4 2023 and has held it in 9 quarters since.
Bailard's Definium Therapeutics position peaked at $295K in Q2 2026.
29 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Bailard's 13F filing for Q3 2026, filed 13 Oct 2026.